There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
周二，Longboard Pharmicals Inc（纳斯达克股票代码：LBPH）发布了太平洋1b/2a期研究的主要数据，该研究评估了贝西卡色林（LP352）治疗与各种发育和癫痫性脑病（DEE）相关的癫痫发作。
Cantor Fitzgerald writes that the data are among the best reported for seizure meds, with a median 53% reduction in seizures across subtypes (~33% placebo adjusted).
坎托·菲茨杰拉德写道，这些数据是癫痫药物报告的最佳数据之一，所有亚型的癫痫发作率中位数下降了53％（经安慰剂调整后约为33％）。
Even though there were just four patients with Dravet Syndrome in the trial, the median seizure reduction achieved with bexicaserin was a remarkable 72%. This level of reduction is comparable to what UCB SA's (OTC: UCBJY) (OTC: UCBJF) Fintepla has demonstrated, a bar Cantor initially believed bexicaserin couldn't reach.
尽管试验中只有四名德拉维特综合征患者，但使用贝西卡色林的发作中位数减少了惊人的72％。这种降低水平与UCB SA（场外交易代码：UCBJY）（场外交易代码：UCBJF）Fintepla所展示的水平相当，坎托最初认为bexicaserin无法达到这一水平。
Cantor says "in light of these excellent results" that the price target for LBPH stock has been raised from $35 to $55, with an overweight rating.
坎托说，“鉴于这些优异的业绩”，LBPH股票的目标股价已从35美元上调至55美元，评级为增持。
Cantor notes that the increased price target might still prove highly conservative since it hasn't yet reflected the broad "DEE" opportunity in the model.
坎托指出，提高的目标股价可能仍非常保守，因为它尚未反映出模型中广泛的 “DEE” 机会。
The analyst awaits additional clarity on that path before incorporating.
在合并之前，分析师正在等待这条道路的进一步澄清。
The analyst lowered the discount rate from 14% to 12% and factored in less dilutive equity raises, given the stock action.
鉴于股票走势，分析师将贴现率从14％下调至12％，并考虑了稀释性较小的股权融资。
Cantor analyst notes LBPH remains a top pick - with even higher conviction now that the program is substantially derisked. The analyst sees peak bexicaserin sales of over $1 billion and potentially over $2 billion.
坎托分析师指出，LBPH仍然是首选——既然该计划已大大降低风险，人们的信心甚至更高。分析师预计，贝西卡塞林的峰值销售额将超过10亿美元，可能超过20亿美元。
Price Action: LBPH shares are up 222.60% at $19.45 on the last check Tuesday.
价格走势：在周二的最后一次支票中，LBPH股价上涨222.60％，至19.45美元。